Memantine in Systemic Lupus Erythematosus

Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to dete... more

Medical trial

ClinicalTrials.gov Identifier:

  • NCT00181298

Type of trial:

Primary outcomes:

  • Change in ANAM, Version 3.11

Start date:

  • Mar 2006

End date:

  • May 2007

Expected total enrollment:

  • 61

Minimum age for eligibility:

  • 18

Eligibility inclusion criteria:

  • Self-reported cognitive impairment
  • Clinical diagnosis of SLE

Eligibility exclusion criteria:

  • Pregnancy
  • Liver or renal insufficiency/failure (calculated creatinine clearance < 50 cc/min)
  • Current alcohol or illicit drug abuse
  • Current use of Namenda, Aricept, Provigil
  • Severe SLE flare in the last 6 weeks (defined as SLEDAI > 12 points)
  • History of non-compliance
  • Recent (within 4 weeks) change in any medication relevant to cognitive function, including prednisone, anti-depressants, medications for insomnia, narcotic medications, attention deficit disorder medications

Health authority:

Treatment being tested:

top ↑

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution